Breast Cancer Treatment Navigator 2026
Beyond "HER2+ or HER2-" — the HER2-Low revolution, ADC breakthroughs, and liquid biopsy are rewriting the rules. Find your molecularly-matched pathway across 7 countries.
Select Your Breast Cancer Subtype
2026 molecular classification: HER2-Low has changed everything. Each card shows the latest standard of care and best country route.
HER2-Low & Ultra-Low NEW PARADIGM
IHC 1+ or IHC 2+/ISH- (Previously "HER2-Negative") — The biggest breakthrough in 2024-2025.
HER2-Positive
IHC 3+ or IHC 2+/ISH+ — ADC-first approach is now standard
Triple-Negative (TNBC)
ER- / PR- / HER2- — Immunotherapy + ADC combinations
HR+ / HER2- (Luminal)
CDK4/6 inhibitors + oral SERDs for ESR1-mutated disease
Navigate by Treatment Pathway
From the ADC revolution to proton therapy — find the optimal destination for each treatment goal.
I Need Next-Gen ADC Therapy (The New Standard)
Antibody-Drug Conjugates (ADCs) are replacing traditional chemo for advanced disease. Targeting HER2, Trop-2, and TROP2 with pinpoint precision.
• T-DXd (HER2): Global standard (DESTINY trials).
• Sacituzumab Govitecan (Trop-2): Approved for TNBC & HR+ (ASCENT / TROPiCS-02).
• Dato-DXd (Trop-2): Latest breakthrough (TROPION-Breast01).
• SHR-A1811 (China Exclusive): Pan-HER ADC showing 75%+ ORR in HER2-Low with superior safety profile. Available via Chinese clinical trials.
- Confirm exact IHC scoring (HER2 0, 1+, 2+, 3+)
- Assess ILD (Interstitial Lung Disease) risk factors
- Evaluate Trop-2 expression for alternative ADCs
- Consider Chinese trials for SHR-A1811 (lower toxicity)
I Need Proton Therapy (Left-Sided Tumors)
Proton therapy reduces cardiac radiation dose by 50-70% compared to conventional radiation for left-sided breast cancer.
- Left-sided tumor confirmation
- Cardiac comorbidity assessment
- Compare proton vs photon plans
I'm CDK4/6-Resistant (Seeking Trials)
After progression on Palbociclib, Ribociclib, or Abemaciclib, next options include novel SERDs, AKT inhibitors, or ADC therapy.
- Liquid biopsy for ESR1/PIK3CA mutations
- Assess prior CDK4/6i duration
- Consider clinical trial vs standard options
Breast Cancer: Country Comparison
Each country plays a distinct role in the breast cancer treatment ecosystem based on drug access, trial availability, and cost.
China
South Korea
Germany
USA
Turkey
Breast Cancer Precision Decision Matrix
Molecularly-matched treatment routing: subtype × biomarker × drug × country × budget.
| Subtype / Biomarker | Latest Standard / Trial Agent | Best Country Route | Budget | Clinical Trigger |
|---|---|---|---|---|
| HR+ / HER2- (ESR1 Mutated) | Oral SERD (Elacestrant) | 🇺🇸 USA / 🇩🇪 Germany | $150K+ | Liquid Biopsy: ESR1+ |
| HR+ / HER2- (PIK3CA/AKT) | AKT Inhibitor (Capivasertib) | 🇬🇧 UK / 🇩🇪 Germany | $120K+ | NGS: PIK3CA/AKT1/PTEN |
| HR+ / HER2-Low (IHC 1+/2+) | T-DXd or SHR-A1811 (Trial) | 🇨🇳 China (SHR-A1811) | $40K-$90K | DESTINY-Breast04/06 criteria |
| HER2+ (Metastatic) | T-DXd 1st line / Tucatinib | 🇰🇷 Korea / 🇺🇸 USA | $200K+ | Brain mets? (Tucatinib) |
| TNBC (PD-L1 CPS ≥10) | Pembrolizumab + Chemo | 🇺🇸 USA / 🇩🇪 Germany | $250K+ | KEYNOTE-522 protocol |
| TNBC (Trop-2 High) | Sacituzumab Govitecan / Dato-DXd | 🇨🇳 China (Trials) | $30K-$70K | ASCENT / TROPION data |
| BRCA1/2 Mutated | PARP Inhibitor (Olaparib) | 🇩🇪 Germany / 🇺🇸 USA | $180K+ | Germline/Somatic NGS |
| Any Subtype (CDK4/6 Resistant) | Dalpiciclib (China) / Novel SERDs | 🇨🇳 China | $25K-$50K | Domestic NMPA approvals |
Navigation Tools & Precision Medicine
Practical tools for genomic-driven breast cancer treatment decisions.
Liquid Biopsy & ctDNA Monitoring
Move beyond tissue. Real-time genomic tracking for metastatic breast cancer.
- ESR1 Mutations: Detect via plasma ctDNA to switch to Elacestrant.
- PIK3CA / AKT1: Blood-based NGS for Capivasertib/Alpelisib eligibility.
- MRD (Minimal Residual Disease): Post-surgery ctDNA clearance tracking.
- China Advantage: Rapid, low-cost NGS panels (7-10 days) via BGI/Geneplus.
Required Documents Checklist
Everything needed for a breast cancer case review.
- Pathology report (ER, PR, HER2 IHC ± FISH)
- Ki-67 index & histologic grade
- Recent PET-CT / CT / Bone Scan (DICOM)
- Complete treatment history (all lines)
- Germline BRCA1/2 testing (if available)
Timeline Estimator
How fast can you access breast cancer treatment?
- China ADC trials (SHR-A1811): 2-4 weeks
- Korea proton therapy: 4-6 weeks
- Germany/USA approved ADCs: 8-12 weeks
- Second opinion: 48 hours
Second Opinion Checklist
Key questions for your breast cancer second opinion.
- Is my HER2 score accurately assessed (HER2-Low vs 0)?
- Am I eligible for an ADC clinical trial?
- Should I get liquid biopsy for ESR1/PIK3CA?
- Which country offers the best access for my subtype?
Disclaimer: This is a decision-support tool, not medical advice. All treatment decisions are made by licensed physicians at partner institutions. Read our full Legal Framework →
Breast Cancer Treatment FAQ
Common questions about HER2-Low, ADCs, and molecular testing.
HER2-Low breast cancer (IHC 1+ or IHC 2+/ISH-) was previously considered HER2-negative. Based on DESTINY-Breast04 and DESTINY-Breast06 trials, these patients now benefit significantly from Trastuzumab deruxtecan (T-DXd). China is also leading trials for SHR-A1811, a next-generation pan-HER ADC with a potentially safer pulmonary profile.
Liquid biopsy detects circulating tumor DNA (ctDNA) in the blood. It is crucial for identifying actionable mutations like ESR1 (indicating the use of oral SERDs like Elacestrant) and PIK3CA/AKT1 (for AKT inhibitors like Capivasertib) without needing an invasive tissue re-biopsy. Chinese labs offer rapid, cost-effective NGS liquid biopsies.
ADCs are 'smart chemotherapy' drugs that use an antibody to find cancer cells (targeting HER2, Trop-2, etc.) and deliver a toxic chemo payload directly inside the cell, sparing healthy tissue. Key ADCs include T-DXd (Enhertu) for HER2+, Sacituzumab govitecan (Trodelvy) for TNBC, and Dato-DXd. China is at the forefront of next-gen ADC clinical trials.
It depends on your subtype: for HER2-Low ADC trials (SHR-A1811), China leads with costs $20K-$80K. For FDA-approved T-DXd, the USA. For proton therapy (left-sided tumors), Korea excels. For CDK4/6-resistant HR+ disease, China's Dalpiciclib offers an affordable alternative. Germany provides premium care across all subtypes.
T-DXd costs approximately $180,000-$250,000 per year in the USA. In China, clinical trials for next-gen ADCs like SHR-A1811 may offer treatment at significantly reduced costs ($20K-$60K). Korea and Germany offer approved T-DXd with insurance coverage for eligible patients.
SHR-A1811 is a novel pan-HER ADC developed in China showing 75%+ objective response rate (ORR) in HER2-Low breast cancer with a potentially lower risk of interstitial lung disease (ILD) compared to T-DXd. It is currently available through Chinese clinical trials at significantly lower cost than T-DXd in Western markets.
Ready to Find Your Breast Cancer Treatment Path?
Submit your case for a free, no-obligation molecular assessment. Our oncology team will match your subtype, biomarkers, and treatment goals with the optimal destination and pathway within 48 hours.
Submit Your Case NowFree • Confidential • 48-Hour Response • No Obligation
3 Responses